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Objectives We determined the outcome of cardiac allografts from multiorgan donors enrolled in a randomized trial of donor
pre-treatment with dopamine.
Background Treatment of the brain-dead donor with low-dose dopamine improves immediate graft function after kidney
transplantation.
Methods A cohort study of 93 heart transplants from 21 European centers was undertaken between March 2004 and
August 2007. We assessed post-transplant left ventricular function (LVF), requirement of a left ventricular assist
device (LVAD) or biventricular assist device (BVAD), need for hemofiltration, acute rejection, and survival of recip-
ients of a dopamine-treated versus untreated graft.
Results Donor dopamine was associated with improved survival 3 years after transplantation (87.0% vs. 67.8%, p 
0.03). Fewer recipients of a pre-treated graft required hemofiltration after transplant (21.7% vs. 40.4%, p 
0.05). Impaired LVF (15.2% vs. 21.3%, p  0.59), requirement of a LVAD (4.4% vs. 10.6%, p  0.44), and
biopsy-proven acute rejection (19.6% vs. 14.9%, p  0.59) were not statistically different between groups. Post-
transplant impaired LVF (hazard ratio [HR]: 4.95; 95% confidence interval [CI]: 2.08 to 11.79; p  0.001), re-
quirement of LVAD (HR: 6.65; 95% CI: 2.40 to 18.45; p  0.001), and hemofiltration (HR: 2.83; 95% CI: 1.20 to
6.69; p  0.02) were predictive of death. The survival benefit remained (HR: 0.33; 95% CI: 0.12 to 0.89; p 
0.03) after adjustment for various risks affecting mortality, including pre-transplant LVAD/BVAD, inotropic sup-
port, and impaired kidney function.
Conclusions Treatment of brain-dead donors with dopamine of 4 g/kg/min will not harm cardiac allografts but appears to
improve the clinical course of the heart allograft recipient. (Prospective Randomized Trial to Evaluate the Effi-
cacy of Donor Preconditioning With Dopamine on Initial Graft Function After Kidney Transplantation;
NCT00115115) (J Am Coll Cardiol 2011;58:1768–77) © 2011 by the American College of Cardiology Foundation
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October 18, 2011:1768–77 Donor Dopamine and Heart Allograft SurvivalOptimized care for deceased heart-beating donors has the
potential to improve outcome in organ transplantation
(1–4). Although current guidelines advocate administration
of inotropic agents for hemodynamic stabilization of the
brain-dead donor, the dosage of dopamine and/or dobut-
amine should be limited to 10 g/kg/min after successful
olume resuscitation, when left ventricular ejection fraction
See page 1778
exceeds 45% (5). However, these recommendations remain
inadequately supported in the literature, because of limited
clinical data from controlled trials, on graft outcome (6,7).
We recently presented a randomized, controlled clinical trial
that showed that pre-treatment of brain-dead donors with
low-dose dopamine of 4 g/kg/min reduces the dialysis
equirement after kidney transplantation (8). The underly-
ng mechanism is related to antioxidant properties of the
opamine molecule (9). In the particular setting of organ
reservation, dopamine increases the tolerance of the kidney
raft to withstand ischemic damage during cold storage.
ence, our findings are not in contrast to the present
vidence, which does no longer warrant the routine use of
opamine in the critically ill with impending or overt renal
ailure (10,11). Before low-dose dopamine can be imple-
ented as a standard in the care of multiorgan donors, the
utcome of nonrenal transplants included in the dopamine
rial remain to be assessed. The present investigation, nested
n the randomized dopamine trial, focuses on the multi-
rgan donor subgroup that also donated the heart for
ransplantation. The study evaluates cardiac transplant re-
ults based on donor assignment to pre-treatment with or
ithout low-dose dopamine.
ethods
tudy design and patients. Rationale, design, and execu-
ion of the randomized dopamine trial were described
lsewhere (8). Briefly, the renal trial was designed to
ompare the dialysis frequency in renal graft recipients.
fter confirmation of brain death, and after consent for
rgan donation, heart-beating donors were randomly as-
igned to receive or not receive a standardized 4 g/kg/min
dopamine infusion until cross clamping. Eligible donors had
to be stable while receiving norepinephrine at a dose not
exceeding 0.4 g/kg/min. Dopamine-treated and untreated
onors were monitored to meet the target parameters of
versity Hospital Regensburg, Regensburg, Germany; ##University Medical Center
Freiburg, Freiburg, Germany; ***University Heart Center Dresden, Dresden, Ger-
many; †††German Heart Center Munich, Munich, Germany; ‡‡‡University Hospi-
tal Münster, Münster, Germany; and the §§§University Hospital Erlangen, Erlan-
gen, Germany. This study was partially supported by a medical school grant from
Novartis Pharmaceuticals, released in November 2002. Dr. Berchtold-Herz is
supported by Thoratec Inc. and Novartis GmbH. All other authors have reported they
have no relationships relevant to the contents of this paper to disclose.m
Manuscript received December 21, 2010; revised manuscript received April 14,
2011, accepted May 10, 2011.emodynamic stability (5). Cir-
ulatory side effects referring to
achycardia and/or hypertension
esulted in dose reduction or a
remature termination of the do-
amine infusion. Taking these
recautions, no circulatory desta-
ilization occurred that rendered
he organs unsuitable for donation.
While planning the renal trial,
consultant statement was re-
uested from the Eurotransplant
eart Advisory Committee to
etermine whether a dopamine
osage of 4 g/kg/min could
ompromise the heart allograft in
ultiorgan donations. The Com-
ittee had no concerns since the
lanned pre-treatment conforms
o current guidelines established for maintaining circulatory
tability in brain-dead donors. All patients on the waiting
ist for heart transplantation consented that their deperson-
lized medical data can be used for scientific analyses.
The randomized dopamine study was carried out in close
ollaboration with the organ procurement organizations of
avaria and Baden-Württemberg. These states have a
opulation of 23 million people. Allocation of donor
rgans, including heart allografts, was centrally directed by
urotransplant. During the recruitment period, from
arch 2004 to August 2007, the vast majority of hearts
ere allocated to critically ill patients with the classification
rgent or highly urgent. In September 2005, highly urgent
as redefined to further prioritize patients with the most
rgent indication for heart transplantation. Only a minority
f patients categorized elective received transplants based on
waiting time algorithm (12,13).
Transplant outcome in recipients was assessed in a similar
ay to the renal study. A questionnaire was sent to heart
ransplant centers after data collection for the renal trial was
ompleted. Response rate to the questionnaire was 100%.
ata on the following outcome measures were collected:
ost-transplant left ventricular function (LVF) assessed by
chocardiography (normal/impaired), need for a left ven-
ricular assist device (LVAD), which reflects primary graft
ysfunction, and hemofiltration after transplantation, since
emofiltration is frequently used particularly for patients
uffering from volume overload due to right ventricular
ysfunction after heart transplantation (14). We also re-
uested information on frequency and severity of in-hospital
pisodes of biopsy-proven acute rejection (AR), allograft
ailure, and death, including date and cause of death during
follow-up period of 3 years after transplantation. Acute
ejections were graded according to the revised International
ociety of Heart and Lung Transplantation (ISHLT) heart
iopsy grading scale (15). In addition, we gathered infor-
Abbreviations
and Acronyms
AR  acute rejection
ATP  adenosine
triphosphate
BVAD  biventricular
assist device
GFR  glomerular filtration
rate
ISHLT  International
Society of Heart and Lung
Transplantation
LVAD  left ventricular
assist device
LVF  left ventricular
function
UNOS  United Network for
Organ Sharingation on relevant medical recipient characteristics, includ-
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Donor Dopamine and Heart Allograft Survival October 18, 2011:1768–77ing underlying heart disease, pre-transplant invasive hemo-
dynamic assessments, pre-transplant LVAD or biventricular
assist device (BVAD) therapy, pre-transplant renal function
and infections, and collected data on cold ischemic time and
immunosuppressive therapy administered within 24 h of
transplantation, according to center practice. Data on ur-
gency classification and time spent on the waiting list were
obtained from Eurotransplant.
Donor transplant characteristics obtained from the stan-
dard Eurotransplant donor information forms included
circulatory and ventilation parameters, laboratory values,
concomitant medication, cold preservation, and organ qual-
ity, as assessed by the cardiac surgeon following harvesting.
Anonymity of donors and recipients was ensured by the use
of the Eurotransplant code numbers for data collection.
Statistical analysis. We evaluated quantitative data by
using 2-sample t tests for means of values, and the Mann-
Whitney U test for medians as appropriate for the data
distribution. Qualitative data were compared with chi-
square or 2-sided Fisher exact tests. Outcome parameters
were primarily analyzed according to the intention-to-treat
principle. Additional analyses were carried out as per pro-
tocol omitting subjects whose dopamine was prematurely
withdrawn, or not given for organizational reasons (Fig. 1).
For time-to-event data, Kaplan-Meier curves were gener-
Figure 1 Flow Diagram for Study Enrollment and Outcomes
After confirmed brain death and given consent to organ donation, donors were ran
sion until cross-clamping. Eligible donors were hemodynamically stable while recei
organs was centrally directed by Eurotransplant, prioritizing recipients with the moated. Because no patient received a second transplant during
the subsequent observation period, patient death also re-
flects graft failure. Log-rank tests were used to test the
equality of the failure/survivor function between groups. For
all parameters analyzed, significance was defined as a
2-sided p  0.05. We applied Cox’s regression to control
or putative confounding donor and recipient related vari-
bles, such as age and sex, the recipient’s comorbidities,
ncluding pre-transplant mechanical support (LVAD/
VAD or intra-aortic balloon pump), pre-transplant ino-
ropic support, pre-transplant kidney function, and donor
dministration of norepinephrine before organ procure-
ent. In addition, a separate Cox regression model was used
o analyze the effects of clustering by site. All results are
resented as hazard ratios (HRs), with a 95% confidence
nterval (CI) for a 1-U change in the variable. Statistical
nalyses were carried out with Stata Statistical Software for
S Windows (Stata Corp., College Station, Texas).
esults
n all, 275 donors were evaluated for study inclusion. Of
hese, 264 met the inclusion criteria, and underwent ran-
omization; 124 donors were assigned to dopamine treat-
ent, and 140 to controls. Of these, 101 donors were
assigned to receive or not receive a standardized 4 g/kg/min dopamine infu-
orepinephrine at a dose not exceeding 0.4 g/kg/min. Allocation of the donor
nt indication for heart transplantation.domly
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October 18, 2011:1768–77 Donor Dopamine and Heart Allograft Survivalscheduled for heart donation. One heart in each group was
not transplanted. To focus on heart transplants, 3 combined
transplants from each study group were excluded from the
primary analysis, because these patients represent a totally
different patient category. Thus, 46 cardiac transplants
assigned to dopamine, and 47 controls were included in the
intention-to-treat analysis. From 46 cardiac transplants
assigned to dopamine, 39 were treated per protocol, 5
discontinued receiving dopamine, 1 had a reduced dose, and
1 never received dopamine because of organizational rea-
sons. Median duration of the dopamine infusion in the
treatment group was 404 min (interquartile range: 222
min). One donor from the control group received dopamine
after being included in the study (Fig. 1).
Fifty-two hearts (55.9%) included in the primary analysis
were retrieved in Bavaria, and 41 (44.1%) came from
Baden-Württemberg. Since Eurotransplant allocation rules
are urgency based, most cardiac grafts went to out-of-state
heart transplantation centers. In Bavaria, 33 hearts (63.5%)
went to out-of-state centers, and 19 (36.5%) were locally
transplanted. The respective numbers in Baden-Württemberg
were 30 hearts (73.2%) to out-of-state centers, and 11 (26.8%)
were locally transplanted.
The study groups had very similar demographic and
clinical donor-recipient characteristics (Tables 1 and 2). In
articular, recipients in both groups were comparable re-
arding pre-transplant invasive hemodynamic assessments,
re-transplant inotropic and mechanical support, kidney
unction, infections, cold ischemic time, and immunosup-
ressive medication after transplantation. Although statis-
ically not significant, urgency status and female to male
ransplants were greater in the no-dopamine group and may
ave placed the controls to a higher risk after transplant.
owever, urgency status and female to male transplants
ere not explanatory variables of graft survival (highly
rgent vs. urgent or elective HR: 0.85; 95% CI: 0.31 to 2.32;
 0.75; female to male vs. male to female or no sex
ismatch HR: 0.68; 95% CI: 0.25 to 1.85; p  0.45).
otably, there were also no between-group differences in
onor hemodynamics, including blood pressure, 24-h urine
roduction, volume state, and donor ventilation parameters,
ncluding acid-base status. However, fewer donors receiving
opamine had norepinephrine during intensive care, al-
hough the used dosage was comparable between groups (33
f 46 [71.7%] vs. 42 of 47 [89.4%], p  0.03). Echocar-
iographic findings before organ recovery were normal,
xcept in 2 hearts from the control group and in 1 heart of
he treatment group, which presented with moderately
mpaired LVF.
Post-transplant impaired LVF (7 of 46 [15.2%] vs. 10 of
7 [21.3%], p  0.59), requirement for LVAD (2 of 46
4.4%] vs. 5 of 47 [10.6%], p  0.44), and biopsy-proven
R (9 of 46 [19.6%] vs. 7 of 47 [14.9%], p 0.59) were not
ound to be statistically different in recipients of dopamine-
reated and untreated grafts. Nevertheless, recipients of a
opamine-treated graft had more favorable in-hospital and pong-term outcomes. Fewer recipients of the treatment group
equired hemofiltration after transplantation (10 of 46 [21.7%]
s. 19 of 47 [40.4%], p  0.05) (Fig. 2, Table 3), although
re-transplant kidney function was not different among the
tudy groups (Table 1). Impaired kidney function of the
ecipients pre-transplant, as defined by a serum creatinine
1.5 mg/dl, was also associated with the requirement for
emofiltration after transplant (12 of 25 [48.0%] vs. 17 of 68
25.0%], p  0.03). Multiple regression confirmed that both
onor dopamine (odds ratio: 0.38, 95% CI: 0.15 to 0.97; p 
.04) and impaired kidney function of the recipient (odds ratio:
.03, 95% CI: 1.12 to 8.19; p  0.03) were independent
xplanatory variables of hemofiltration after transplant.
When the analysis was limited to recipients with a cardiac
llograft treated as per protocol, which means that the
onors of the treatment group had received the dopamine
nfusion until cross-clamping, the statistical association of
onor dopamine and a reduced requirement for hemofiltra-
ion became stronger, and the advantageous effect was
nhanced (requirement for hemofiltration 7 of 39 [18.0%]
s. 19 of 46 [41.3%], p  0.03) (Fig. 2, Table 3).
ontinuous dopamine infusion until cross-clamping was
lso associated with a reduced mortality 3 months after
ransplantation (2 of 39 [5.1%] vs. 10 of 46 [21.7%], p 
.03). When data were analyzed on intention-to-treat basis,
he beneficial effect on mortality at 3 months (4 of 46 [8.7%]
s. 10 of 47 [21.3%], p 0.10) missed the level of statistical
ignificance (Fig. 2).
Impaired LVF on echocardiography (HR: 4.95; 95% CI:
.08 to 11.79; p  0.001), requirement for LVAD (HR:
.65; 95% CI: 2.40 to 18.45; p 0.001), and hemofiltration
fter transplantation (HR: 2.83; 95% CI: 1.20 to 6.69; p 
.02) were predictive of a recipient’s death, but occurrence
f a biopsy-proven AR episode during the in-hospital stay
as not (HR: 1.50; 95% CI: 0.55 to 4.10; p 0.43). In fact,
he majority of deaths occurred in patients who required
emofiltration after transplantation (11 of 29 [37.9%] vs. 10
f 64 [15.6%], hemofiltration vs. no hemofiltration, p 
.02). Post-transplant patient and allograft survival of the
ntire study cohort was 90.3%, 81.7%, and 77.3% after 1,
2, and 36 months, respectively. Donor pre-treatment with
opamine resulted in a significant effect on allograft survival
years after transplantation (87.0% vs. 67.8%, p  0.03)
Fig. 3). This survival benefit remained when combined
ransplants, which had been excluded from the primary
nalysis, were added to the survival data (85.7% vs. 65.7%,
 0.02).
Causes of mortality at 3 months were the following: in
he dopamine group, 3 patients died of primary graft failure
nd 1 of myocardial infarction. In the no-dopamine group,
died of multiorgan failure, 2 of primary graft failure, and
of pneumonia. During follow-up, 7 additional deaths
ccurred: 2 in the dopamine group (1 multiorgan failure, 1
ejection) and 5 in the no-dopamine group (1 each of
ardiovascular event, lung cancer, rejection, infectious com-
lication, and unknown cause).
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Donor Dopamine and Heart Allograft Survival October 18, 2011:1768–77Baseline Characteristics of RecipientsTable 1 Baseline Characteristics of Recipients
Dopamine
(n  46)
No Dopamine
(n  47) p Value
Demographics
Age, yrs 56 (48–62) 56 (50–62) 0.96
Female 10 (21.7%) 10 (21.3%) 0.96
Underlying heart disease 0.19
Ischemic heart disease 25 (54.4%) 17 (36.2%)
Dilated cardiomyopathy 18 (39.1%) 27 (57.4%)
Other* 3 (6.5%) 3 (6.4%)
Time on waiting list, days 146 (51–354) 141 (62–511) 0.62
Pre-transplant hemodynamics, most recent assessment†
Systemic blood pressure
Systolic, mm Hg 99 14 102 15 0.34
Diastolic, mm Hg 62 11 61 11 0.65
Cardiac index, l/min/m2 1.9 0.3 1.8 0.4 0.35
Mixed venous oxygen saturation, % 53 10 51 8 0.26
Pulmonary artery pressure
Systolic, mm Hg 45 13 43 15 0.47
Diastolic, mm Hg 22 7 21 8 0.84
Mean, mm Hg 31 9 30 10 0.48
Mean PCWP, mm Hg 23 7 21 9 0.25
PVRI, Wood units/m2 3.9 (2.6–5.6) 4.7 (2.9–6.3) 0.39
Pre-transplant inotropic support
Dopamine 13 (28.3%) 9 (19.2%) 0.34
Dobutamine 16 (34.8%) 18 (38.3%) 0.73
Adrenaline 5 (10.9%) 4 (8.5%) 0.74
Milrinone 12 (26.1%) 10 (21.3%) 0.63
Pre-transplant mechanical support
LVAD/BVAD 10 (21.7%) 12 (25.5%) 0.67
IABP 3 (6.5%) 2 (4.3%) 0.68
Pre-transplant kidney function, most recent assessment
Serum creatinine, mg/dl 1.31 0.50 1.28 0.45 0.75
Serum creatinine 1.5 mg/dl 13 (28.3%) 12 (25.5%) 0.77
Renal replacement therapy 0 (0%) 1 (2.1%) 0.99
Pre-transplant infections 0.99
LVAD/BVAD 2 (4.4%) 3 (6.4%)
Invasive lines/drains 1 (2.2%) 0 (0%)
Transplant characteristics
Donor/recipient sex mismatch 14 (30.4%) 17 (36.2%) 0.56
Female to male 12 (26.1%) 17 (36.2%) 0.37
Male to female 2 (4.4%) 0 (0%) 0.24
Donor/recipient weight ratio 1.05 0.17 1.02 0.16 0.46
Urgency code 0.22
Highly urgent 33 (71.7%) 40 (85.1%)
Urgent 4 (8.7%) 1 (2.1%)
Elective 9 (19.6%) 6 (12.8%)
Panel reactive antibody 5% 2 (4.4%) 1 (2.1%) 0.62
Cold ischemic time, min‡ 206 52 207 58 0.91
Immunosuppressive medication§
CNI 45 (97.8%) 44 (93.6%) 0.62
MMF/MPA 29 (63.0%) 30 (63.8%) 0.94
mTOR inhibitors 2 (4.4%) 5 (10.6%) 0.44
Corticosteroids 46 (100.0%) 46 (97.8%) 0.99
Values are median (interquartile range), n (%), or mean SD. *Other includes hypertrophic cardiomyopathy (n 2), valvular heart disease (n 1),
amyloidosis (n  1), congenital heart disease (n  1), ventricular arrhythmia (n  1). †Excluding patients on pre-transplant LVAD/BVAD. ‡Data on
cold ischemic time was not documented in 1 patient of the dopamine-treated group. One heart of either group was warm preserved on Organ Care
System. §Administered according to the center’s practice within 24 h before or after transplantation.
BVAD  biventricular assist device; CNI  calcineurin inhibitors; IABP  intra-aortic balloon pump; LVAD  left ventricular assist device; MMF 
mycophenolatemofetil; MPAmycophenolic acid; mTORmammalian target of rapamycin; PCWP pulmonary capillary wedge pressure; PVRI
pulmonary vascular resistance index.
lutarat
EEP 
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October 18, 2011:1768–77 Donor Dopamine and Heart Allograft SurvivalA separate analysis of graft recipients from the dopamine
group, but not pre-treated as per protocol, showed that
patient survival was 71.4% at both 12 and 36 months. This
result was very similar to the observed survival rate in the
no-dopamine group (Table 3). Median infusion time in
those donors, who were prematurely withdrawn from do-
pamine due to circulatory side effects, was 60 min only. All
side effects referring to tachycardia and hypertension were
transient and fully reversible after termination of the dopa-
mine infusion (8).
Clustering by site had no effect on mortality. Site of
procurement (Bavaria HR: 1.11; 95% CI: 0.47 to 2.64; p 
Baseline Characteristics of DonorsTable 2 Baseline Characteristics of Donors
Demographics
Age, yrs 4
Female 2
Cause of brain death
Trauma 1
Intracranial bleeding 2
Laboratory values, most recent assessment
Hemoglobin, g/l
Leukocytes, 109/l 1
Sodium, mmol/l
Potassium, mmol/l
Serum creatinine, mg/dl 0
Glucose, mg/dl
Hemodynamic parameters
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Urine production during last 24 h, l 4
Urine production during last h, ml 17
CVP, mm Hg
Ventilation parameters
PEEP, cm H20
PaO2/FiO2, mm Hg
PaCO2, mm Hg
Base excess, mmol/l
pH 7
Concomitant donor treatment
Norepinephrine 3
Dose (g/kg/min) 0.0
Desmopressin
Prednisolone 1
Cold perfusion*
UW Solution
HTK Solution 3
Other
Organ quality assessment†
Good 3
Acceptable
Values are median (interquartile range), n (%), or mean  SD. *K
dopamine-treated and untreated group, respectively. †Rated by the ca
the dopamine-treated and untreated group, respectively.
CVP  central venous pressure; HTK  histidine-tryptophane-ketog
partial pressure of arterial oxygen to the fraction of oxygen inspired; P0.81) and of transplantation (out-of-state centers HR: 0.73;95% CI: 0.30 to 1.76; p  0.49) did not alter the HRs. The
advantageous effects of dopamine treatment persisted in the
multiple Cox regression analysis (HR: 0.33; 95% CI: 0.12 to
0.91; p  0.03). Although norepinephrine was more fre-
quently applied to the no-dopamine group, its use (HR:
0.67; 95% CI: 0.20 to 2.30; p  0.53) did not affect the
principal finding of the study (Table 4).
Discussion
This study indicates that pre-treatment of brain-dead do-
nors with low-dose dopamine may considerably improve the
ine
46)
No Dopamine
(n  47) p Value
51) 43 (31–50) 0.90
5%) 27 (57.5%) 0.18
1%) 14 (29.8%) 0.69
5%) 25 (53.2%) 0.75
17 106 17 0.66
4.5 12.8 5.9 0.13
8 147 9 0.85
0.5 4.2 0.5 0.27
0.29 0.82 0.22 0.72
35 139 39 0.14
16 128 17 0.95
11 70 12 0.87
–6.1) 4.5 (3.0–5.7) 0.50
–260) 140 (100–200) 0.06
3 6 3 0.11
3 7 3 0.94
97 312 118 0.44
9 38 6 0.27
3.4 0.4 3.3 0.35
0.06 7.43 0.06 0.78
7%) 42 (89.4%) 0.03
3–0.11) 0.07 (0.04–0.12) 0.63
4%) 32 (68.1%) 0.17
0%) 22 (46.8%) 0.34
0.61
4%) 11 (23.4%)
1%) 30 (63.8%)
%) 2 (4.3%)
0.79
4%) 37 (78.7%)
9%) 7 (14.9%)
perfusion solution was not documented in 2 and 4 donors of the
urgeon upon organ procurement. Four and 3 hearts were not rated in
e; paCO2  partial pressure of arterial carbon dioxide; paO2/FiO2 
positive end-expiratory pressure; UW  University of Wisconsin.Dopam
(n 
5 (33–
0 (43.
2 (26.
6 (56.
107
4.4
147
4.1
.84
127
128
70
.4 (3.4
8 (110
7
7
294
40
1.0
.42
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Donor Dopamine and Heart Allograft Survival October 18, 2011:1768–77plantation. The most striking finding was that fewer recip-
ients of a dopamine-treated graft died during a follow-up of
3 years, although pre-transplant donor cardiac function and
the recipients’ physical disability on the waiting list were
very similar in the dopamine group and control group. The
overall survival rates of the cohort analyzed in the present
Figure 2 Requirement of Hemofiltration and Mortality at 3 Mon
Data are displayed (left) on intention-to-treat, and (right) on per-protocol analyses
Clinical OutcomesTable 3 Clinical Outcomes
Variable
Intention-to-Treat An
Dopamine (n  46) No Dopamin
Events occurring after transplantation
Impaired LVF on echocardiography 7 (15.2%) 10 (21
Requirement of LVAD 2 (4.4%) 5 (10
Requirement of hemofiltration 10 (21.7%) 19 (40
Acute biopsy-proven rejection episode* 9 (19.6%) 7 (14
Grade 0–1 6 (13.0%) 7 (14
Grade 2–3 3 (6.5%) 0 (0%
Mortality at 3 months 4 (8.7%) 10 (21
Long-term allograft/patient survival†
At 12 months 91.3% 72.3
At 24 months 87.0% 70.2
At 36 months 87.0% 67.8Values are n (%) or %. *According to the revised International Society of Heart and Lung Transplantation
LVAD  left ventricular assist device; LVF  left ventricular function.study are in line with recent continent-specific data from the
ISHLT registry at 1 and 3 years, and hence, reflect current
standards of care for adult heart transplantation in Europe
(16). In our study, 78.5% of the recipients were listed as
highly urgent and 5.4% as urgent at time of transplantation
(Table 1). The proportion of patients who were trans-
According to Donor Pre-Treatment With Dopamine
lines  dopamine; red lines  no dopamine. HF  hemofiltration.
Per-Protocol Analysis
47) p Value Dopamine (n  39) No Dopamine (n  46) p Value
0.59 5 (12.8%) 10 (21.7%) 0.39
0.44 1 (2.6%) 5 (10.9%) 0.21
0.05 7 (18.0%) 19 (41.3%) 0.03
0.59 8 (20.5%) 6 (13.0%) 0.39
6 (15.4%) 6 (13.0%)
2 (5.1%) 0 (0%)
0.15 2 (5.1%) 10 (21.7%) 0.03
0.02 94.9% 71.7% 0.007
0.05 89.7% 69.6% 0.02
0.03 89.7% 69.6% 0.02ths,
. Bluealysis
e (n 
.3%)
.6%)
.4%)
.9%)
.9%)
)
.3%)
%
%
%heart biopsy grading scale (15). †Values are Kaplan-Meier estimates over time.
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October 18, 2011:1768–77 Donor Dopamine and Heart Allograft Survivalplanted in the U.S. between 2004 and 2007 with adult
candidate status 1A and 1B was 43.1% and 35.4%, respec-
tively (17). Although the Organ Procurement and Trans-
plantation Network and the United Network of Organ
Sharing (OPTN/UNOS) adult candidate status for heart
transplantation differs from the Eurotransplant urgency
classification to some extent, the higher proportion of
critically ill patients in our study may partly explain the
inferior outcome results as compared to the OPTN and the
Scientific Registry of Transplant Recipients (OPTN/
SRTR) database (17).
Regarding early clinical events, fewer recipients of a
pre-treated graft required hemofiltration after transplant,
although there were no between-group differences in pre-
transplant kidney function. Furthermore, post-transplant
LVF impairment, requirement of a LVAD, and mortality at
3 months were consistently reduced in recipients of a
pre-treated graft but failed to reach the level of significance,
presumably because of lack in statistical power. The inci-
ence of acute renal failure after heart transplantation as
efined by the requirement of renal replacement therapy
efore discharge from the hospital ranges from 6% to 40%
14,18,19). The rather frequent use of hemofiltration in our
tudy was driven by 2 independent factors, which were
onor dopamine and the recipients’ impaired kidney func-
ion. In fact, 48% of recipients with an elevated serum-
reatinine pre-transplant required hemofiltration after
ransplant.
Because the administration of dopamine to the donors
recludes any interference with kidney function in the
ecipient, it was an intriguing finding that dopamine af-
ected the need for hemofiltration independently from
re-existing renal failure. Acute renal failure after heart
Figure 3
Kaplan-Meier Estimates of Patient
Survival After Heart Transplantation,
According to Donor Pre-Treatment With Dopamine
Data are displayed as intention to treat. Blue line  dopamine;
red line  no dopamine. Mo  months.ransplantation is caused by various pre-disposing factors,including graft dysfunction (19,20). In particular, right
ventricular dysfunction is a frequent complication after heart
transplantation (21), which presumably remained underdi-
agnosed in our study to some extent. Serial Swan-Ganz
catheter measurements after transplant were unavailable,
since invasive lines were removed in the majority of cases
immediately after transplantation to minimize the risk of
invasive line related infections in the immunosuppressed
cardiac transplant recipient. Echocardiography, which en-
ables a reasonable estimate of LVF, is rather insensitive to
evaluate right ventricular function. Given its greater depen-
dency on loading conditions right ventricular ejection frac-
tion is a poor measure of true right ventricular function (22),
which may have prevented the diagnosis of right ventricular
failure in less severe cases. Hemofiltration is frequently used
to correct an underlying refractory volume overload in
instances of deteriorating glomerular filtration rate (14).
ardiac dysfunction accompanied by acute renal failure is
nown to increase post-operative mortality after cardiac
urgery and after heart transplantation (23,24). In accor-
ance with these data, need for hemofiltration significantly
redicted allograft failure and mortality in our study. None-
heless, the post-operative use of hemofiltration and post-
perative graft failure rates were relatively high compared to
on-European transplant centers, so the generalizability of the
esults regarding the magnitude of benefit from donor pre-
reatment may be less in situations where graft failure is less
ikely.
Since donor hemodynamic stability under low-dose nor-
pinephrine was a prerequisite of eligibility for study inclu-
ion (8), the beneficial effects of dopamine should not be
een as a consequence of an additional circulatory stabiliza-
ion of the deceased donor. Even though the individual
osage of norepinephrine did not differ between groups, it
as more frequently used in the control group. However,
ncluding norepinephrine as an explanatory variable into the
ultiple Cox regression model failed to influence the
rincipal finding of this study.
Cardiac allografts are highly susceptible to prolonged cold
schemia. There is evidence that ischemic time negatively
ffects allograft survival in adult heart transplantation (25).
Multiple Cox Regression of Recipient MortalityTable 4 Multiple Cox Regression of Recipient Mortality
Hazard Ratio 95% CI p Value
Donor dopamine pre-treatment 0.33 0.12–0.89 0.03
Donor age, yrs 1.01 0.97–1.06 0.53
Donor on norepinephrine 0.67 0.20–2.30 0.53
Recipient age, yrs 1.01 0.96–1.05 0.79
Recipient female 1.48 0.50–4.37 0.48
Recipient on mechanical
support pre-transplant
1.69 0.60–4.76 0.32
Recipient on inotropic support
pre-transplant
0.71 0.27–1.89 0.49
Recipient with elevated serum
creatinine pre-transplant
1.05 0.41–2.69 0.92CI  confidence interval.
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part ascribed to oxidative stress (26,27). Under cold storage
conditions, the accumulation of reactive oxygen species
leads to an increased release of calcium ions from intracel-
lular stores, and from the extracellular environment through
store-operated channels (28). A vicious circle is activated,
because intracellular calcium homeostasis depends on high-
energy phosphates that maintain the mitochondrial mem-
brane potential. While synthesis of ATP is decreased under
hypothermia, the influx of calcium further exhausts ATP.
Abundant intracellular calcium aggravates mitochondrial
damage, with the consequence that the mitochondrial
membrane potential ultimately breaks down (29). Strategies
that reduce intracellular calcium with novel hyperpolarizing
preservation solutions have been shown to ameliorate isch-
emic damage during cold preservation in experimental heart
transplantation (27). We were able to demonstrate that
dopamine decelerates the deleterious amplification loop of
intracellular calcium accumulation, and subsequent ATP
consumption by scavenging of reactive oxygen species
(9,30). These findings have been recently expanded and
confirmed by in vitro studies with cardiomyocytes in culture
(31). Serial biopsies from human donor hearts, taken at
pre-defined time points during the pre-operative and post-
operative transplantation procedure, indicated an increased
risk of graft failure if the heart failed to replenish its ATP
stores within 10 min after reperfusion (21). Obviously, the
cardiac allograft is highly dependent on a sufficient supply of
high energy phosphates to meet the circulatory demands
after transplantation.
The net effects of donor pre-treatment, and the statistical
associations in our study became stronger when the analyses
were done as per protocol. This observation suggests that
it is crucial to continue the dopamine infusion until cross-
clamping. Dopamine is inactivated by oxidative deamination
by mitochondrial monoamine oxidase and by O-methylation
by catechol-O-methyltransferase. This rapid enzymatic degra-
dation accounts for a half-life of a few minutes when dopamine
is circulating in the blood (32,33). Dopamine’s ability to
protect against cold preservation injury depends on its diffusion
into cells (34). Hence, to facilitate dopamine accumulation
within the intracellular compartment, it is of utmost impor-
tance that a pharmacokinetic steady state is achieved before
cold preservation. This view is supported by our observation
that recipients of a pre-treated graft that was prematurely
withdrawn from dopamine due to transient side effects had
very similar survival rates as the no-dopamine group.
Study limitations. The randomized dopamine trial was
designed to assess the incidence of dialysis after transplan-
tation in renal transplant patients. Neither study endpoints
nor a quantitative hypothesis that included sample size
calculations was pre-specified during the planning phase for
heart allograft recipients. Albeit reaching statistical signifi-
cance, the beneficial effect mediated through donor dopa-
mine treatment derives from a relatively small study cohort
of cardiac transplant recipients, limiting the external validityof our findings. Under formal considerations, our study is a
post-hoc analysis that was nested in a randomized con-
trolled clinical trial. As in the renal trial, we evaluated the
frequency of biopsy proven AR during the in-hospital
period after transplantation, and assessed long-term patient
and graft survival. In addition, we selected early clinical
events, such as a required LVAD and need for hemofiltra-
tion, which are well known to predict mortality after
transplantation (16). The principal limitation of the open-
label study design, where endpoints are based on therapeutic
interventions, is well recognized. Theoretically, it can not be
excluded that knowledge of study interventions in the donor
influenced the indication for therapy in the recipient.
However, it was deemed unlikely that the indication for
treatment with a LVAD or hemofiltration was initiated by
other factors than organ dysfunction in the cardiac trans-
plant recipient. Nonetheless, both outcome measures were
highly predictive of mortality in our study, which is defi-
nitely a hard endpoint devoid of classification bias.
A major strength of the present investigation is its high
internal validity. No recipient was lost, and follow-up data
are complete for a minimum of 2 years after transplantation.
The study evaluates a multicenter transplant activity under
real-life conditions, where transplant recipients were not
exposed to protocol-mandated interventions. Clustering by
site failed to reveal an effect on the principal outcome of
long-term patient and graft survival. Most importantly,
although the study was strictly observational in the recipi-
ents, the donor’s treatment was carried out according to a
prospective, randomized study design, which enhanced the
reliability of the study findings beyond the potential of
selection bias.
Conclusions
This study shows that donor pre-treatment with low-dose
dopamine does not harm the cardiac allograft but appears to
improve the clinical course of the heart allograft recipient
after transplantation. It is suggested that low-dose dopa-
mine for heart-beating multiorgan donors with confirmed
brain death should receive further evaluation by a prospec-
tive randomized controlled trial as no adverse side-effects
have been recognized in the recipients, whereas it has the
potential to considerably improve the outcome after both
kidney and heart transplantation.
Reprint requests and correspondence: Dr. Peter Schnuelle,
University Medical Centre Mannheim, 5th Department of Med-
icine, Theodor Kutzer Ufer 1-3, Mannheim 68167, Germany.
E-mail: peter.schnuelle@umm.de.
REFERENCES
1. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive
pharmacologic donor management results in more transplanted or-
gans. Transplantation 2003;75:482–7.
1777JACC Vol. 58, No. 17, 2011 Benck et al.
October 18, 2011:1768–77 Donor Dopamine and Heart Allograft Survival2. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal
resuscitation yields more transplanted hearts, with improved early
function. Transplantation 2003;75:1336–41.
3. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal
therapy of the brain-dead organ donor: experimental and clinical
studies. Transplantation 2006;82:1396–401.
4. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects
of catecholamine application to brain-dead donors on graft survival in
solid organ transplantation. Transplantation 2001;72:455–63.
5. Wood KE, Becker BN, McCartney JG, D’Alessandro AM, Coursin
DB. Care of the potential organ donor. N Engl J Med 2004;351:
2730–9.
6. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City
meeting to maximize the use of organs recovered from the cadaver
donor. Am J Transplant 2002;2:701–11.
7. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus confer-
ence report: maximizing use of organs recovered from the cadaver
donor: cardiac recommendations, March 28–29, 2001, Crystal City,
Virginia. Circulation 2002;106:836–41.
8. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pre-
treatment with dopamine on graft function after kidney transplanta-
tion: a randomized controlled trial. JAMA 2009;302:1067–75.
9. Brinkkoetter PT, Song H, Lösel R, et al. Hypothermic injury: the
mitochondrial calcium, ATP and ROS love-hate triangle out of
balance. Cell Physiol Biochem 2008;22:195–204.
10. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose
dopamine in patients with early renal dysfunction: a placebo-controlled
randomised trial. Australian and New Zealand Intensive Care Society
(ANZICS) Clinical Trials Group. Lancet 2000;356:2139–43.
11. Galley HF. Renal-dose dopamine: will the message now get through?
Lancet 2000;356:2112–3.
12. van den Hout WB, Smits JM, Deng MC, et al. The heart-allocation
simulation model: a tool for comparison of transplantation allocation
policies. Transplantation 2003;76:1492–7.
13. Komoda T, Hetzer R, Lehmkuhl HB. Influence of new Eurotrans-
plant heart allocation policy on outcome of heart transplant candidates
in Germany. J Heart Lung Transplant 2008;27:1108–14.
14. Hoskote A, Carter C, Rees P, Elliott M, Burch M, Brown K. Acute
right ventricular failure after pediatric cardiac transplant: predictors
and long-term outcome in current era of transplantation medicine.
J Thorac Cardiovasc Surg 2010;139:146–53.
15. Billingham M, Kobashigawa JA. The revised ISHLT heart biopsy
grading scale. J Heart Lung Transplant 2005;24:1709.
16. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International
Society for Heart and Lung Transplantation: Twenty-sixth official
adult heart transplant report–2009. J Heart Lung Transplant 2009;28:
1007–22.
17. The 2009 OPTN/SRTR Annual Report: Tables 11.4 and 11.11.
Available at: http://optn.transplant.hrsa.gov/ar2009/. Accessed on
April 8, 2011.
18. Boyle JM, Moualla S, Arrigain S, et al. Risks and outcomes of acute
kidney injury requiring dialysis after cardiac transplantation. Am J
Kidney Dis 2006;48:787–96.
19. Jokinen JJ, Tikkanen J, Kukkonen S, et al. Natural course and risk
factors for impaired renal function during the first year after heart
transplantation. J Heart Lung Transplant 2010;29:633–40.20. Garrido IP, Crespo-Leiro MG, Paniagua MJ, et al. Independent predic-
tors of renal dysfunction after heart transplantation in patients with
normal pre-transplant renal function. J Heart Lung Transplantation
2005;24:1226–30.
21. Stoica SC, Satchithananda DK, Atkinson C, et al. The energy
metabolism in the right and left ventricles of human donor hearts
across transplantation. Eur J Cardiothorac Surg 2003;23:503–12.
22. Poston RS, Griffith BP. Heart transplantation. J Intensive Care Med
2004;19:3–12.
23. Gummert JF, Bucerius J, Walther T, et al. Requirement for renal
replacement therapy in patients undergoing cardiac surgery. Thorac
Cardiovasc Surg 2004;52:70–6.
24. Ouseph R, Brier ME, Jacobs AA, Erbeck KM. Continuous veno-
venous hemofiltration and hemodialysis after orthotopic heart trans-
plantation. Am J Kidney Dis 1998;32:290–4.
25. Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA, Bonser
RS. The importance of cold and warm cardiac ischemia for survival
after heart transplantation. Transplantation 2008;86:542–7.
26. Southard JH, Belzer FO. Organ preservation. Annu Rev Med 1995;
46:235–47.
27. Hoenicke EM, Sun X, Strange RG Jr., Damiano RJ Jr. Donor heart
preservation with a novel hyperpolarizing solution: superior protection
compared with University of Wisconsin solution. J Thorac Cardiovasc
Surg 2000;120:746–54.
28. Ahlenstiel T, Burkhardt G, Kohler H, Kuhlmann MK. Bioflavonoids
attenuate renal proximal tubular cell injury during cold preservation in
Euro-Collins and University of Wisconsin solutions. Kidney Int
2003;63:554–63.
29. Haddad P, Cabrillac JC, Piche D, Musallam L, Huet PM. Changes in
intracellular calcium induced by acute hypothermia in parenchymal,
endothelial, and Kupffer cells of the rat liver. Cryobiology 1999;39:
69–79.
30. Brinkkoetter PT, Beck GC, Gottmann U, et al. Hypothermia-induced
loss of endothelial barrier function is restored after dopamine pre-
treatment: role of p42/p44 activation. Transplantation 2006;82:534–42.
31. Hepp C, Vettel C, Benck U, et al. Both dopamine and its derivative
N-octanoyl-dopamine protect cardiomyocytes against cold preserva-
tion injury (abstr). Am J Transplant 2010;10:194.
32. Homcy CJ, Graham RM. Molecular characterization of adrenergic
receptors. Circ Res 1985;56:635–50.
33. Yan M, Webster LT Jr., Blumer JL. Kinetic interactions of dopamine
and dobutamine with human catechol-O-methyltransferase and
monoamine oxidase in vitro. J Pharmacol Exp Ther 2002;301:315–21.
34. Yard B, Beck G, Schnuelle P, et al. Prevention of cold-preservation
injury of cultured endothelial cells by catecholamines and related
compounds. Am J Transplant 2004;4:22–30.
Key Words: antioxidants y cardiac transplantation y dopamine y
ischemia y survival.
APPENDIX
For a list of investigators who made invaluable contributions to this study,
please see the online version of this article.
